In the wake of the recent NIH funding cuts, the biotech industry is facing unprecedented challenges that threaten the very foundation of medical innovation. The NIH has long been a crucial source of support for early-stage research and development, providing essential funding for groundbreaking discoveries and clinical trials.
With the drastic reduction in funding, biotech startups are now forced to navigate a landscape fraught with financial, clinical, and operational risks. However, amidst these challenges, there are strategic steps that companies can take to not only survive but thrive in this new environment. Diversifying funding sources, strengthening investor relations, and forming strategic partnerships are just a few of the key strategies that can help biotech startups weather the storm and continue to drive innovation in the industry.
Read more on biospace.com
You might also like: Living Logic: How Gene Circuits Are Reprogramming Biology